A class-action lawsuit accuses CVS Caremark of denying medically necessary treatments by stopping coverage of Zepbound, Eli Lilly’s blockbuster weight-loss drug. CVS Caremark stopped covering Zepbound ...
(CNN) — A class-action lawsuit has been filed against CVS Caremark over its decision to stop covering Zepbound, Eli Lilly’s blockbuster GLP-1 drug to treat obesity. When the major pharmacy benefit ...
Caremark, the pharmacy benefit manager owned by CVS Health (NYSE:CVS), is reportedly trying to get Novo Nordisk (NVO) to agree to cover a month's supply of its blockbuster GLP-1 weight loss treatment ...
(CNN) — A class-action lawsuit has been filed against CVS Caremark over its decision to stop covering Zepbound, Eli Lilly’s blockbuster GLP-1 drug to treat obesity. When the major pharmacy benefit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback